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Abstract
Background: Relatively few U.S.-based studies in chronic kidney disease have focused on Asian/
Pacific Islanders. Clinical reports suggest that Asian/Pacific Islanders are more likely to be affected
by IgA nephropathy (IgAN), and that the severity of disease is increased in these populations.
Methods: To explore whether these observations are borne out in a multi-ethnic, tertiary care
renal pathology practice, we examined clinical and pathologic data on 298 patients with primary
glomerular lesions (IgAN, focal segmental glomerulosclerosis, membranous nephropathy and
minimal change disease) at the University of California San Francisco Medical Center from
November 1994 through May 2001. Pathologic assessment of native kidney biopsies with IgAN was
conducted using Haas' classification system.
Results: Among individuals with IgAN (N = 149), 89 (60%) were male, 57 (38%) white, 53 (36%)
Asian/Pacific Islander, 29 (19%) Hispanic, 4 (3%) African American and 6 (4%) were of other or
unknown ethnicity. The mean age was 37 ± 14 years and median serum creatinine 1.7 mg/dL. Sixty-
six patients (44%) exhibited nephrotic range proteinuria at the time of kidney biopsy. The
distributions of age, gender, mean serum creatinine, and presence or absence of nephrotic
proteinuria and/or hypertension at the time of kidney biopsy were not significantly different among
white, Hispanic, and Asian/Pacific Islander groups. Of the 124 native kidney biopsies with IgAN, 10
(8%) cases were classified into Haas subclass I, 12 (10%) subclass II, 23 (18%) subclass III, 30 (25%)
subclass IV, and 49 (40%) subclass V. The distribution of Haas subclass did not differ significantly by
race/ethnicity. In comparison, among the random sample of patients with non-IgAN glomerular
lesions (N = 149), 77 (52%) patients were male, 51 (34%) white, 42 (28%) Asian/Pacific Islander, 25
(17%) Hispanic, and 30 (20%) were African American.
Conclusions: With the caveats of referral and biopsy biases, the race/ethnicity distribution of
IgAN differs significantly from that of other major glomerulonephridities. However, among
individuals undergoing native kidney biopsy, we see no evidence of a race/ethnicity association with
severity of disease in IgAN by clinical and IgAN-specific histopathologic criteria. Further studies are
needed to identify populations at higher risk for progressive disease in IgAN.
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Background
IgA nephropathy (IgAN) is the most common form of
glomerulonephritis (GN) worldwide [1]. Approximately
20–30% of individuals with IgAN develop end-stage renal
disease (ESRD) by 10–20 years following diagnosis [2].
Despite the increasing recognition of IgAN as a significant
cause of chronic kidney disease (CKD), no specific thera-
pies for IgAN have been developed. Glucocorticoids and
fish oil have been recommended for selected patients with
IgAN based on controversial results from small clinical tri-
als [3-5]. Many patients with IgAN receive no specific
therapy.
Clinical reports suggest that individuals of Asian/Pacific
Islander heritage are more likely to be affected by IgAN
than whites, African Americans, and persons of Hispanic
descent. Reports from U.S. centers have generally com-
pared results of white and African American IgAN
patients, with little or no available information on U.S.
patients of Asian/Pacific Islander heritage. Studies from
Japan and China have reported that more individuals
with ESRD in these countries had IgAN, implying that
IgAN may have a more severe disease course in certain
Asian populations [6,7].
To explore whether IgAN was more common and severe
among Asian/Pacific Islanders in our population, we
examined clinical and pathologic data on 149 patients
with IgAN and a random sample of 149 patients with
other primary glomerular lesions (focal segmental
glomerulosclerosis, membranous nephropathy and mini-
mal change disease) at the University of California San
Francisco (UCSF) Medical Center.
Methods
The records of 183 percutaneous native and transplant
kidney biopsies with a diagnosis of IgAN received
between November 1994 and May 2001 at the Renal
Pathology Laboratory at UCSF were reviewed. Baseline
demographic and clinical data included age, gender, race
or ethnicity, history of kidney transplant, date of biopsy,
and serum creatinine concentration at the approximate
time of biopsy. In addition, the presence or absence of
heavy proteinuria (≥ 3.0 g/day, with or without the neph-
rotic syndrome) and the presence or absence of hyperten-
sion at the time of biopsy were recorded. Major ethnic
groups included white, Asian/Pacific Islander, Hispanic,
African American, and other/unknown. Ethnicity was
determined using information from patient health insur-
ance forms and history provided at the time of biopsy.
Any case in which Henoch-Schönlein purpura, systemic
lupus erythematosus or chronic liver disease were consid-
ered likely diagnoses were excluded, as were cases of IgAN
superimposed on a systemic disease involving the kidney
(e.g., diabetic nephropathy). Two examiners unaware of
the clinical data independently reviewed the biopsies.
Biopsies displaying fewer than six glomeruli by light
microscopy or insufficient immunofluorescence staining,
as defined below, were also excluded. Fifteen biopsies
were additionally excluded due to incomplete recovery of
microscopic slides from files. Biopsies from 149 patients,
including 25 kidney transplant recipients, satisfied the cri-
teria for inclusion and provided the basis for the IgAN
analytic sample.
Aside from IgAN, the most commonly diagnosed primary
glomerular lesions at our institution over the same time
period were focal segmental glomerulosclerosis (N =
314), membranous nephropathy (N = 197) and minimal
change disease (N = 147). To establish baseline race/eth-
nicity prevalences for our region and referral population,
we collected demographic data on a computer-generated
random sample of individuals with non-IgAN glomerular
disease (N = 149), stratified by kidney transplant.
Pathologic assessment
Pathologic assessment of the IgAN native kidney biopsies
was performed based on Haas' IgA nephropathy classifica-
tion system [8]. All cases included in the study also met
the following criteria: (1) immunofluorescence studies
showing at least 2+ (scale 0 to 3+) mesangial deposition
of IgA, with IgA comprising the dominant immunoglobu-
lin deposited in the glomeruli, and (2) electron micros-
copy (EM) studies showing the presence of mesangial
deposits.
Statistical analysis
Demographic and clinical data are reported as mean ±
standard deviation, medians with interquartile ranges,
and proportions with 95% confidence limits. Inter-eth-
nicity comparisons were performed using the Cochrane-
Mantel-Haenzsel χ2 test for categorical variables, and anal-
ysis of variance (general linear models) or Kruskal-Wallis
test for continuous variables. Two-tailed P-values <0.05
were considered statistically significant. SAS version 8.2
was used for all statistical analyses (SAS Institute, Cary,
NC, USA).
Results
Patient clinical characteristics for the IgAN group are sum-
marized in Table 1. Eighty-nine (60%) patients were male
and 60 (40%) were female. Fifty-seven (38%) patients
were white, 53 (36%) Asian/Pacific Islander, 29 (19%)
Hispanic, 4 (3%) African American and 6 (4%) were of
other or unknown race/ethnicity. The mean age of the
IgAN patients at the time of kidney biopsy was 37 ± 14
years. Among the three main ethnic groups (whites, His-
panics, and Asian/Pacific Islanders), Hispanic patients
tended to be slightly younger at the time of biopsy com-
pared with whites and Asian/Pacific Islanders. TheBMC Nephrology 2004, 5:10 http://www.biomedcentral.com/1471-2369/5/10
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distributions of age and gender, however, did not differ
significantly among white, Hispanic, and Asian/Pacific
Islander groups.
The median serum creatinine (SCr) of the IgAN cohort
was 1.7 mg/dL (interquartile range 1.1–3.4 mg/dL). The
median SCr of the African American group was signfi-
cantly higher (5.0 mg/dL) than the other ethnic groups;
however, these calculations were based on a small sample
size (N = 4) due to the low prevalence (3%) of African
Americans with in our IgAN cohort. Median serum creati-
nine concentrations were not significantly different
among white, Hispanic, and Asian/Pacific Islander groups
(P = 0.64). Sixty-six patients (44%) exhibited heavy (≥ 3
g/d) proteinuria, and 74 (50%) had documented hyper-
tension (systolic blood pressure ≥ 140 or diastolic blood
pressure ≥ 90 mm Hg) at the time of kidney biopsy. The
fractions of patients with heavy proteinuria and hyperten-
sion at the time of kidney biopsy were not significantly
different among white, Hispanic, and Asian/Pacific
Islander groups.
Of the 124 native kidney biopsies, the majority of cases
(64%) fell into Haas subclasses IV or V, which are known
independent predictors of progressive disease and poor
renal outcomes [2,8]. Only 22 biopsies (18%) were
graded as Haas subclasses I or II, reflecting a relatively
high threshold for kidney biopsy in our referral region.
The distribution of Haas subclass did not differ signifi-
cantly among race/ethnicity groups.
Table 2 shows the demographic characteristics of the IgAN
and non-IgAN groups. Among the random sample of
patients (N = 149) with non-IgAN primary glomerulopa-
thies, 67 (45%) patients had focal segmental glomerulo-
sclerosis (FSGS), 58 (39%) membranous nephropathy,
and 24 (16%) minimal change disease. Seventy-seven
(52%) patients were male, 51 (34%) white, 42 (28%)
Asian/Pacific Islander, 25 (17%) Hispanic, and 30 (20%)
were African American. In contrast to previous reports, the
distribution of gender did not differ significantly between
the IgAN and non-IgAN groups (P = 0.16) [8]. Patients in
the non-IgAN group were, however, significantly older
(mean age 42 ± 21 years vs. 37 ± 14 years, P = 0.006) com-
pared to patients with IgAN. In addition, the distribution
of race/ethnicity differed significantly between the two
groups (P < 0.001). This association of IgAN and distribu-
tion of race/ethnicity persisted even when stratified by
kidney transplant (P < 0.001 for native kidney compari-
son,  P  = 0.006 for kidney transplant recipient
comparison).
Discussion
In a biopsy series of 244 patients with IgAN, Haas found
fewer African Americans (in a major urban setting), simi-
lar to that noted in other U.S.-based studies of IgAN [9-
11]. While limited by the size of certain ethnic groups in
the study population, Haas found no significant differ-
ence in renal survival associated with "white race, black
race or Hispanic origin" [8]. The reason for a lower preva-
lence of IgAN in African Americans relative to other kid-
ney diseases remains unclear. The frequency of IgAN in
African Americans does not appear to be influenced by the
higher prevalence of the IgA2 allotype among this group
[12].
Table 1: Summary characteristics: IgA nephropathy
Characteristica Total (N = 149) White (N = 57) Asian/PIb (N = 53) Hispanic (N = 29) African American 
(N = 4)
Unknown 
(N = 6)
P-valuec
Mean age (yr) 37 ± 14 38 ± 15 37 ± 15 34 ± 14 26 ± 22 36 ± 24 0.54
Mean SCr (mg/dL) 3.1 ± 3.8 3.0 ± 2.6 3.1 ± 4.5 2.9 ± 4.2 6.3 ± 6.2 2.7 ± 2.9 0.96
Male, N (%) 89 (60) 37 (65) 29 (55) 16 (55) 3 (75) 4 (67) 0.50
Proteinuria ≥ 3g/d, N (%) 66 (44) 28 (49) 20 (37) 13 (45) 3 (75) 2 (33) 0.08
Hypertension, N (%) 74 (50) 28 (49) 28 (53) 14 (48) 2 (50) 3 (33) 0.86
Transplant, N (%) 25 (17) 4 (7) 13 (24) 8 (28) 0 (0) 0 (0) 0.15
Haas subclassd, N (%)
I 10 (8) 4 (8) 5 (13) 0 (0) 0 (0) 1 (17) 0.76
II 12 (10) 5 (9) 4 (10) 2 (10) 0 (0) 1 (17)
III 23 (19) 10 (19) 8 (20) 2 (10) 1 (25) 2 (32)
IV 30 (24) 13 (24) 8 (20) 7 (33) 1 (25) 1 (17)
V 49 (40) 21 (40) 15 (37) 10 (47) 2 (50) 1 (17)
aValues represent mean ± standard deviation.
bAsian/Pacific Islander
cP-value refers to overall NOVA, Kruskal-Wallis test, or χ2 for comparison of white, Asian/Pacific Islander and Hispanic groups.
dHaas subclass assessment performed on native kidney biopsies (N = 124).BMC Nephrology 2004, 5:10 http://www.biomedcentral.com/1471-2369/5/10
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In our study, the fraction of biopsies in subclasses I and II
(18%) was similar to that observed by Haas (23%). How-
ever, we observed a higher proportion of biopsies in sub-
classes IV and V (64% vs. 31%), and a lower proportion of
biopsies in subclass III (19% vs. 45%) compared with
Haas, possibly reflecting a temporal trend towards a
higher biopsy threshold along with intergrader measure-
ment bias.
In a study reviewing the pattern of glomerulonephritis in
Singapore over the past two decades, Woo and colleagues
reported that IgAN was the most common primary GN
occurring in Singapore (42% of all primary GNs in the
first decade and 45% in the second decade) [13]. In our
biopsy population during the same period that we stud-
ied, IgAN represented 12.8% of all biopsies with primary
glomerular diseases and 8.4% of all biopsies (excluding
transplant biopsies for non-glomerular diseases). In
China, Li reported that IgAN was the leading cause of
ESRD, accounting for approximately 18% of patients [6].
In a national survey of Japanese patients with ESRD,
Koyama et al. reported that 28% of new dialysis patients
had IgAN listed as their primary cause of ESRD. Moreover,
due to the number of additional biopsies showing chronic
glomerulonephritis without immunofluorescent micro-
scopic descriptions in the survey, the authors estimated
that possibly 40% of newly registered dialysis patients in
Japan might have had CKD from IgAN. In contrast, only
0.8% of incident ESRD patients in the U.S. have docu-
mented or suspected IgAN [14]. Katznelson and Cecka,
using data from the United Network for Organ Sharing
(UNOS), have also reported a higher incidence of IgAN
and chronic glomerulonephritis causing ESRD in Asian/
Pacific Islander American recipients of renal allografts
between 1991 and 1996 [15].
In contrast, based on smaller biopsy series, a striking var-
iation in prevalence rates of IgAN has been reported from
Europe and South America. In the UK, for example, Ballar-
die and colleagues noted comparatively low prevalence
rates of IgAN in a predominantly white population (Man-
chester, England) in the early 1970's. In the subsequent
15-year period, however, these investigators reported a
phenomenal rise in the observed incidence of IgAN
(accounting for 31% of all glomerulopathies in 1986),
which the investigators felt more likely reflected a higher
frequency of detection rather than true rise in disease inci-
dence. Similar prevalence rates have also been docu-
mented from isolated white populations in Finland and
southern Italy [16,17]. In contrast, few studies have
addressed the epidemiology of IgAN in Latin America. In
a small Brazilian single-center cohort (N = 205) of pri-
mary glomerular diseases, Mazzarolo et al. reported rela-
tively modest prevalence rates (10.2%) of IgAN [18]. A
larger series (N = 1,263) of renal biopsies from Peru noted
much lower prevalence rates of IgAN, which accounted for
only 0.9% of all glomerular lesions over a 10-year period
at a central reference renal pathology laboratory in Lima
[19].
These differences may be partially attributed to increased
screening and disparities in the indication for kidney
biopsy. In Japan and South Korea, for example, school-
aged children undergo annual screening for urinary
abnormalities; kidney biopsy is subsequently recom-
mended for children with evidence of proteinuria or
hematuria [20]. More comprehensive yearly health exams
are further performed on full-time salaried employees
throughout Japan, Singapore, and Hong Kong, making
detection more likely in these ethnic groups. Furthermore,
a significant reporting bias may also contribute to the
higher reported prevalence rates of IgAN in Asian/Pacific
Islanders, e.g., in the study by Koyama et al., only 502
Table 2: Patient demographics: All glomerular lesions
Characteristica IgA nephropathy (N = 149) Non-IgAN glomerular lesionsb (N = 149) P-valuec
Mean age (years) 37 ± 14 42 ± 21 0.006
Male, N (%) 89 (60) 77 (52) 0.16
Transplant, N (%) 25 (17) 25 (17) 1.00
Race/ethnicity, N (%)
White 57 (38) 51 (34) <0.001
African American 4 (3) 30 (20)
Asian/PId 53 (36) 42 (28)
Hispanic 29 (19) 25 (17)
Other/Unknown 6 (4) 1 (1)
aValues represent mean ± standard deviation.
bFocal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease.
cP-value refers to overall ANOVA, Kruskal-Wallis test, or χ2.
dAsian/Pacific IslanderBMC Nephrology 2004, 5:10 http://www.biomedcentral.com/1471-2369/5/10
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(7%) of the approximate 6800 patients diagnosed with
IgAN had undergone a confirmatory kidney biopsy [7].
Although the etiology of IgAN remains unknown, there
exists a strong suspicion for an environmental antigen
trigger combined with a genetic susceptibility factor.
Along these lines, several hypotheses have been proposed
to account for the reportedly higher prevalence of IgAN in
Asian/Pacific Islanders. With respect to potential dietary
antigens, Wakai et al. found that high intake of rice and n-
6 polyunsaturated fatty acids (PUFA) were associated with
an increased risk of IgAN [21]. Recent reports from Japan
have also suggested a potential role of H. parainfluenzae as
a causative agent of IgAN in Japanese children and adults.
Such claims are supported by studies showing the glomer-
ular deposition of outer membrane H. parainfluenzae anti-
gens and greater levels of plasma IgA1 antibody against
OMHP in Japanese patients with IgAN (compared to Jap-
anese patients with other renal diseases) [22,23]. Whether
Japanese, or Asian/Pacific Islanders in general, have
higher rates of H. parainfluenzae colonization and/or
infection has yet to be established.
The presence of either hypertension or proteinuria ≥ 3.0 g/
24 hrs at the time of diagnosis significantly correlated
with worsened renal survival in IgAN, even when control-
ling for serum creatinine at the time of kidney biopsy [2].
We found no difference in the distribution of Haas sub-
class, hypertension and nephrotic proteinuria among
Caucasians, Asian/Pacific Islanders, and Hispanics.
Despite ongoing investigative efforts, scant data are avail-
able regarding genetic markers that may predispose indi-
viduals to progressive disease from IgAN. Recent
immunogenetic studies have suggested a potential role for
the T-cell receptor (TCR) in the development of immune-
mediated diseases. Deenitchina and colleagues found that
genetic polymorphism of the TCR constant alpha chain
was associated with progression of CKD in a cohort of Jap-
anese patients with IgAN. Although promising, such pol-
ymorphisms of the TCR gene have yet to be evaluated in
large, prospective studies or by genetic analysis of familial
IgAN [24].
Our results contest the assertion that IgAN follows a more
severe course in individuals of Asian/Pacific Islander
descent. One reason for the similar disease severity of
IgAN in our study population may stem in part from the
large subpopulation of Filipino patients comprising our
Asian/Pacific Islander cohort. It is unclear whether certain
subpopulations of Asian/Pacific Islanders, including Fili-
pinos, exhibit IgAN prevalence rates similar to those doc-
umented by Koyama and Woo. Anecdotal reports from
Thailand and India documenting prevalence rates of 4–
9% suggest that IgAN may not have the same epidemiol-
ogy among all southeast Asians [1]. Despite having higher
incidence rates of ESRD than the U.S. white population,
the Asian/Pacific Islanders remain a largely unstudied
group, for whom more comprehensive data collection is
warranted.
There are several important limitations to this report. As
with any single-center biopsy series, we may have been
underpowered to detect a clinically significant difference
due to the limited sample size (type II error). In addition,
racial admixture may have also confounded the results, as
we were unable to subclassify patients in the Asian/Pacific
Islander group or account for the growing population of
bi- or multi-ethnic individuals in our population. Further-
more, due to the study's case control design, and breadth
of our referral base (northern California and Hawaii), we
were unable to control for the criteria for kidney biopsy.
As a result, a biopsy bias may have confounded our
results. In other words, Asian/Pacific Islander patients in
our referral base with mild to moderate proteinuria and/
or hematuria might have been given a presumptive diag-
nosis of IgAN without nephrology referral or confirmatory
kidney biopsy. With regard to disease prevalence, these
potential referral and biopsy biases based on race/ethnic-
ity are largely conservative in nature, and would have
biased our results towards the null. Finally, we have
included data from a modest-sized IgAN transplant popu-
lation (N = 25), the donor demographics of which were
unavailable at the time of the study. However, the associ-
ation of race/ethnicity and distribution of glomerular
lesion persisted, even when stratified by kidney trans-
plant, and thus our overall conclusions remained the
same. In addition, a small European study of donor-recip-
ient pairs (average follow-up 7 years) has shown that
when a donor kidney with asymptomatic IgA deposits is
transplanted into a recipient with ESRD secondary to a
disease other than IgAN, the IgA immune deposits in the
donor kidney are rapidly removed [25].
Conclusions
In conclusion, with the caveats of referral bias and biopsy
bias, the race/ethnicity distribution of IgAN differs signif-
icantly from that of other major glomerulonephridities.
However, among individuals undergoing native kidney
biopsy, we see no evidence of a race/ethnicity association
with severity of disease in IgAN by clinical and IgAN-spe-
cific histopathologic criteria. Further studies are needed to
identify populations at higher risk for progressive disease
in IgA nephropathy.
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